2021.03.11 I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
2021.03.03 I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
2021.02.25 I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin alfa in Pediatric Patients with Growth Hormone Deficiency
2021.02.10 I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
2021.02.09 Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced